Designing Shelf-Stable, Dry Powder Vaccines To Improve Global Access And Pandemic Response

By Sana Hosseini, Senior Scientist, Respiratory Delivery, Lonza; Kim Shepard, Director of Respiratory Delivery, Lonza; and John Chen, Scientist, Access to Advanced Healthcare Institute

The global burden of communicable, infectious diseases, particularly in low-income countries with limited resources, reflects the necessity of developing innovative vaccine delivery solutions. Traditional vaccine formulations often require complex cold chain distribution and storage, limiting their accessibility and hindering efforts to combat diseases like tuberculosis. Dry powder vaccines, on the other hand, offer a potential solution for widespread tuberculosis treatment and prevention, as well as several benefits, including eliminating the need for a cold chain, simplifying distribution, and improving global access.

To support this effort, leading drug companies and manufacturers are exploring how to develop shelf-stable, dry powder vaccines to ensure stability and efficacy for the patient. By understanding the advancements in this field, we can envision a future where vaccines are more readily available and accessible to populations worldwide, empowering us to combat infectious diseases more effectively. Download the full article to explore how spray-dried vaccine formulations have the potential to reduce the global disease burden.